Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles.
In the U.S., lung cancer is the leading cause of cancer death and the second most common cancer.1 Approximately 25-30 percent of non-small cell lung cancers, the most common form of lung cancer, are squamous cell carcinomas. However, there are limited treatment options available for squamous cell carcinomas and development of treatments has been further complicated by the number of potential genetic mutations associated with this form of cancer. Research has demonstrated that squamous cell lung cancer has more than double the genetic mutations compared to other forms of cancer.
Lung-MAP is a biomarker-driven, multi-drug, multi-arm Phase 2/3 registration clinical trial for patients with squamous cell lung cancer. The trial will evaluate five investigational compounds intended to treat squamous cell lung cancer and use genomic sequencing to assign enrolled patients to the treatment arms most likely to provide benefit. Patients will then be randomized into one of five sub-studies where they will receive either standard of care (docetaxel or erlotinib) or biomarker-driven targeted therapy with an investigational agent. Each of these sub-studies will be independently powered for overall survival (OS) with an interim analysis for progression-free survival (PFS) to determine whether to proceed from Phase 2 into Phase 3.
Approximately 500 to 1,000 patients will be screened each year for more than 200 cancer-related genes, and the screenings will inform trial arm selection. Five investigational drugs have been selected for inclusion in the initial trial, including Amgen's rilotumumab, an investigational fully human monoclonal antibody designed to inhibit cancer cell growth and migration.
"Amgen has been at the forefront of biomarker research in an effort to help the medical community understand the different mechanisms of cancer progression and ensure that patients receive treatments that will provide the greatest benefit," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This latest collaboration can significantly speed our understanding of targeted approaches for this complex and underserved form of lung cancer, while demonstrating how genomic testing can drive the evolution of clinical trial design. It may ultimately tell us more about how best to match patients to the right treatments."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Capitalize On 'life Transitions' To Instill Better Environmental Behaviors
- Study Shows North Atlantic Ocean CO2 Storage Doubled Over Last Decade
- Sexual Tensions and the Numbers Game a Systemic Issue Behind #astroSH
- When Conservationists Stop With 'Park Vs. People' Thinking, Wildlife Wins
- From Genes To Latrines: Vikings And Their Worms Provide Clues To Emphysema
- Targeted Axillary Dissection Of Lymph Nodes After Chemotherapy Improves Staging Accuracy Of Node-positive Breast Cancer
- Slender Mice, Heart Disease And Diabetes -- What Do They Have In Common?
- "So there is no why like Bob Fletcher or as some people say you can already see it on Russian news..."
- "Hi Joe, yes the thing is - all that is fine, it's logical from your point of view. And whatever..."
- " Like I asked David Brin: Who are the ones who are actually insane? Certainly it is NOT the skeptics..."
- "https://www.youtube.com/watch?v=nVyV4L072jY So then what is going on in this video? Also what is..."
- "Just curious, When was the last time you (the author) generated a mathematical model? On what?..."
- Florida Declares Zika Virus State of Emergency
- Indonesia’s Many Human Physical Deformities: A Closer Look
- Spinal ‘Column’: Love for Hunchback Dog, Breakthrough for 8-Yr-Old Girl
- BMI is Bologna
- Energy Drinks: The Dose Makes the Poison
- California’s Prop 65: Bad For Public Acceptance Of Science, About To Get Worse
- Cambridge researcher develops smartphone app to map Swiss-German dialects
- Studies link healthy workforces to positive stock market performance
- Pioneering discovery leads to potential preventive treatment for sudden cardiac death
- Online shopping might not be as green as we thought
- Gene family turns cancer cells into aggressive stem cells that keep growing